Blonde, L., Belousova, L., Fainberg, U., Garcia-Hernandez, P., Jain, S., Kaltoft, M., . . . Réa, R. (2019). OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial. J Endocr Soc.
Chicago-стиль цитированияBlonde, Lawrence, et al. "OR22-1 Liraglutide As Add-on to SGLT2 Inhibitors in Patients With Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial." J Endocr Soc 2019.
MLA-цитированиеBlonde, Lawrence, et al. "OR22-1 Liraglutide As Add-on to SGLT2 Inhibitors in Patients With Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial." J Endocr Soc 2019.